{"id":6291,"date":"2024-07-25T14:41:04","date_gmt":"2024-07-25T18:41:04","guid":{"rendered":"https:\/\/www.ast-inc.com\/?p=6291"},"modified":"2025-12-03T16:14:50","modified_gmt":"2025-12-03T21:14:50","slug":"the-new-annex-1-what-it-means-for-the-pharmaceutical-and-fill-finish-industry","status":"publish","type":"post","link":"https:\/\/www.ast-inc.com\/blogs\/the-new-annex-1-what-it-means-for-the-pharmaceutical-and-fill-finish-industry\/","title":{"rendered":"A Closer Look at the New Annex 1: What\u2019s included and What It Means for the Fill-Finish Industry"},"content":{"rendered":"

With the revised Annex 1<\/strong><\/a> coming into effect last year, \u00a0the pharmaceutical industry continues to strategize the best way to attain and maintain compliance with the intensive regulation on sterile medicinal products. Aseptic fill-finish manufacturing, for its part, is established on precise science and the highest standards of safety. While much of the science, technology, mechanisms, and regulations behind parenteral drug products are complicated and nuanced, the net goal is simple: to fill a container with drug product in a way that ensures product integrity and patient safety.<\/strong> How the industry and stakeholders collectively work towards this goal is predicated on best practices, technological implementation and innovation, and robust regulatory frameworks. Central among those frameworks is EU GMP Annex 1 with the following stated purpose:<\/p>\n

\u201cThe manufacture of sterile products covers a wide range of sterile product types (active substance, excipient, primary packaging material and finished dosage form), packed sizes (single unit to multiple units), processes (from highly automated systems to manual processes) and technologies (e.g. biotechnology, classical small molecule manufacturing systems and closed systems). This Annex provides general guidance that should be used in the design and control of facilities, equipment, systems and procedures used for the manufacture of all sterile products applying the principles of Quality Risk Management (QRM), to ensure that microbial, particulate and endotoxin\/pyrogen contamination is prevented in the final product.\u201d<\/em><\/p>\n

As with any new or updated regulation, there were plenty of questions to greet the new Annex 1 upon its adoption. \u00a0Why did this version expand so significantly upon its predecessor? What\u2019s the full scope of the regulation as it stands, and what are the expectations around compliance? \u00a0How should US manufacturers view Annex 1? \u00a0And how should the increased emphasis on robotics, automation, and barrier technologies be viewed?<\/p>\n

Annex 1: A Story of Collaboration<\/h2>\n

Pharmaceutical manufacturing is an internationally oriented and interconnected industry. Technologies, innovations, breakthroughs, and collaborations can come from every corner of the globe. It\u2019s not uncommon for smaller-sized manufacturers, who excel at producing any number of precise technologies, to serve regular international customers. In the larger context of treatment and patient care, one of the great unifiers in our world is the ability of multiple countries, governmental groups, organizations and companies to come together in the fight against illness and disease. The drafting process of the new Annex 1 reflected this same spirit as regulatory bodies, think tanks, and experts from all over the world provided recommendations and feedback for what content should be included in the document. All in all, the document presents the view of the European Commission, the international PIC\/S<\/a> (Pharmaceutical Inspection Convention & Pharmaceutical Inspection Co-operation Scheme), and the World Health Organization,<\/a> and is the most comprehensive, collaborative regulatory document ever authored. The PIC\/S alone includes over 56 regulatory authorities, including the US Food and Drug Administration.<\/p>\n

And while it is an EU regulation, it reflects US standards and the criteria inspectors will be evaluating, as evidenced by the FDA\u2019s participation and explained at a recent ISPE panel discussion with regulatory heads of the FDA, EMA and MHRA<\/a>.<\/p>\n

An Expanded Principle<\/h2>\n

The 2023 Annex 1 was not only significantly expanded in length (58 pages compared to 16 pages from the 2008 version) but also introduced a new structure (categories, chapters, document map, and a glossary of terms<\/a>) and in-depth coverage of any areas directly related to manufacturing sterile products. The principle, in seven detailed sections, highlights the special requirements needed to minimize contamination and calls for a comprehensive Quality Risk Management approach (when identifying and evaluating any risk to quality), and a Contamination Control Strategy that \u201c\u2026should establish a robust assurance of contamination prevention<\/em>.\u201d<\/p>\n

In greater detail, Annex 1 encourages the use of \u201cappropriate technology<\/em>\u201d, specifically mentioning isolators, RABs, and robotic systems\u2014a significant choice by the authoring committee and an indication of the superiority of these solutions as it pertains to sterility assurance and quality management.<\/p>\n

The in-depth principle is a departure from and improvement on its predecessor and informs the guidance throughout the rest of the document, including premises, equipment, production & specific technologies, and environment\/process monitoring.<\/p>\n

Critical Themes:<\/h2>\n

Contamination Control Strategy<\/em><\/strong><\/h3>\n

Contamination Control Strategy (CCS)is a term introduced in the revised Annex 1 and is defined in the regulation as:<\/p>\n

\u201cA planned set of controls for microorganisms, endotoxin\/pyrogen and particles, derived from current product and process understanding that assures process performance and product quality. The controls can include parameters and attributes related to active substance, excipient and drug product materials and components, facility and equipment operating conditions, in-process controls, finished product specifications, and the associated methods and frequency of monitoring and control.\u201d<\/em><\/p>\n

Pharmaceutical manufacturers, of course, had many of the elements of CCS built into their own Quality Management System that were informed by various risk assessment protocols. But in including it as a comprehensive regulatory concept, Annex 1 put forth the most stringent, harmonized approach for product safety and integrity ever by a regulatory presence.<\/p>\n

\"\"<\/p>\n

Figure 1. Scope of CCS as outlined in section 2.5 of the regulation<\/p>\n

First Air<\/em><\/h3>\n

The revised Annex 1 emphasizes the proper configuration and use of unidirectional airflow and spotlights the importance and priority of the \u201cFirst Air\u201d principle. These terms are defined in the Annex as:<\/p>\n